New concepts in human oncology: is it possible to use them in veterinary medicine as well?

In human oncology, novel targeted therapy focusing on monoclonal antibodies and tyrosine kinase inhibitors has become an attractive anticancer strategy. The introduction of antiangiogenetic drugs and metronomic chemotherapy has also increased the therapeutic arsenal. Chemotherapy still plays a key role in the treatment of many tumors affecting dogs and cats. However, novel anticancer strategies (including tyrosine kinase inhibitors and monoclonal antibodies, as well as antiangiogenetic treatments) are becoming relevant in veterinary medicine, too. The goal of this review is to describe new therapeutic strategies for cancer treatment in veterinary medicine, including less well-known chemotherapeutic drugs.     

Histologic margins and the residual tumour classification scheme: Is it time to use a validated scheme in human oncology to standardise margin assessment in veterinary oncology?

There is no consensus on the definition of a complete histologic excision in veterinary oncology; many definitions have been used in various studies, but these have been arbitrarily selected with no apparent justification. The residual tumour classification scheme, where a complete histologic excision is defined as a histologic tumour‐free margin >0 mm, has been used for >40 years in human oncology by all of the major clinical staging organizations and is considered highly prognostic for the vast majority of malignant tumours in people. Because of the widespread use of the residual tumour classification scheme both clinically and in research studies, this standardized approach permits better communication between clinicians, an evidence‐based decision‐making process for adjuvant treatment options following surgical resection, minimizes exposing patients to unnecessary adjuvant treatments and a better ability to compare local tumour control for specific tumours between different studies. The adoption of the residual tumour classification scheme in veterinary oncology would likely achieve similar outcomes and minimize the prevalent confusion within the veterinary community, amongst both general practitioners and specialists, regarding the definition of what constitutes a complete histologic excision.     

Can more be learned from selection experiments of value in animal breeding programmes? Or is it time for an obituary?

Selection experiments in laboratory animals and livestock have provided a wealth of information on genetic parameters of quantitative traits and on the effectiveness of selection in the short and long term on both directly selected and correlated traits. They have stimulated developments in theory and tests of it, and extreme selected lines continue to be source material for biological study. Some of the main questions and findings are briefly reviewed. Yet much of successful animal breeding practice has been based essentially on statistical methods, assuming where necessary the infinitesimal model, and new developments such as genomic selection are similarly not based on selection experiments. Information on the genetic architecture of quantitative traits is provided by selection experiments, but new methods for deeper studies of the biology are available. I discuss the future role for selection experiments in view of changes in funding streams and technology and conclude that there is little case for starting new experiments, but retention of existing long-term lines is desirable and DNA should be collected from all lines on a continuing basis.